Our studies demonstrated that treatment of glioblastoma cells with simvastatin or lovastatin causes a dose-dependent decrease in RAB38 expression and cell viability in LN229, T98G, and GBM43 cells in vitro (Figure 6, Supplementary Figure S2), which to the best of our knowledge has not been reported previously. The gene discussed is RAB38; the disease is glioblastoma.